Assertio Therapeutics (ASRT) Misses Q3 EPS by 14c

Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.01, $0.14 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $35.63 million versus the consensus estimate of $49.92 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c